Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SVRA
SVRA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SVRA News
Savara Inc. Grants Inducement Awards to New Employees
3d ago
Newsfilter
Savara's FDA Review Period Extended for Molgramostim
4d ago
seekingalpha
Savara's FDA Review for Molgramostim Delayed by Three Months
5d ago
stocktwits
Savara's Drug Review Period Extended to November 2026
5d ago
Newsfilter
VR Adviser Increases Stake in Savara by Over 1 Million Shares
Mar 15 2026
NASDAQ.COM
VR Adviser Increases Stake in Savara by Over 1 Million Shares
Mar 15 2026
Fool
Savara Reports Q4 and FY 2025 Financial Results
Mar 13 2026
seekingalpha
Savara Achieves Regulatory Milestones for MOLBREEVI in Autoimmune PAP
Mar 13 2026
Newsfilter
SAVARA ANNOUNCES 2025 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS ALONG WITH BUSINESS UPDATE
Mar 13 2026
moomoo
Savara Receives FDA Day 74 Letter, MOLBREEVI Progressing Smoothly
Mar 06 2026
Newsfilter
SAVARA INC AIMS TO FILE MAA WITH UK MHRA BY END OF Q1 2026
Mar 06 2026
moomoo
Savara Seeks FDA Approval for Molbreevi to Treat Rare Lung Disease
Feb 21 2026
stocktwits
FDA Grants Priority Review for Savara's Molbreevi BLA Resubmission
Feb 20 2026
seekingalpha
Savara Receives FDA Priority Review for MOLBREEVI BLA Submission
Feb 20 2026
Businesswire
Savara Receives Priority Review for MOLBREEVI, Potential First Therapy for Autoimmune PAP
Feb 20 2026
Newsfilter
Savara Secures $150M Non-Dilutive Capital for MOLBREEVI Launch
Jan 27 2026
Newsfilter
Show More News
